Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- Sponsors Aucta Pharmaceuticals
- 12 Sep 2019 Planned End Date changed from 1 Jan 2019 to 1 Apr 2021.
- 12 Sep 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2020.
- 30 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.